Analyst Price Targets — SUPN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:19 pm | — | Craig-Hallum | $65.00 | $57.58 | StreetInsider | Supernus Pharmaceuticals (SUPN) PT Raised to $65 at TD Cowen |
| December 19, 2025 12:50 pm | Annabel Samimy | Stifel Nicolaus | $55.00 | $49.28 | TheFly | Supernus price target raised to $55 from $50 at Stifel |
| October 8, 2025 11:34 pm | — | Piper Sandler | $65.00 | $48.00 | TheFly | Supernus upgraded to Overweight from Neutral at Piper Sandler |
| September 30, 2025 12:42 pm | — | Cantor Fitzgerald | $63.00 | $47.41 | TheFly | Supernus price target raised to $63 from $46 at Cantor Fitzgerald |
| August 29, 2025 10:36 am | — | Piper Sandler | $40.00 | $45.12 | TheFly | Supernus price target raised to $40 from $36 at Piper Sandler |
| July 29, 2025 8:08 pm | — | Cantor Fitzgerald | $42.00 | $33.45 | TheFly | Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald |
| September 11, 2024 4:55 am | David Amsellem | Piper Sandler | $36.00 | $33.49 | TheFly | Piper downgrades Supernus to Neutral on slower Qelbree growth |
| May 24, 2024 7:28 am | David Amsellem | Piper Sandler | $41.00 | $27.85 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN) |
| April 8, 2024 10:10 am | Irene Buhalo | Jefferies | $40.00 | $32.27 | StreetInsider | Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830' |
| April 8, 2024 10:09 am | Annabel Samimy | Stifel Nicolaus | $38.00 | $32.27 | StreetInsider | Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor' |
Latest News for SUPN
ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, celebrates the five-year anniversary of the U.S. Food and Drug Administration (FDA) approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity…
Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SUPN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.